TROV vs. ALEC, ACOG, CHRS, VIGL, CGEN, PLX, CCCC, NMRA, EXOZ, and IVVD
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Alector (ALEC), Alpha Cognition (ACOG), Coherus BioSciences (CHRS), Vigil Neuroscience (VIGL), Compugen (CGEN), Protalix BioTherapeutics (PLX), C4 Therapeutics (CCCC), Neumora Therapeutics (NMRA), Exozymes (EXOZ), and Invivyd (IVVD). These companies are all part of the "medical" sector.
Cardiff Oncology vs.
Cardiff Oncology (NASDAQ:TROV) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
Alector has a consensus target price of $4.00, suggesting a potential upside of 222.58%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Cardiff Oncology.
Cardiff Oncology has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
In the previous week, Alector had 7 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Alector and 0 mentions for Cardiff Oncology. Alector's average media sentiment score of 0.72 beat Cardiff Oncology's score of 0.00 indicating that Alector is being referred to more favorably in the news media.
Cardiff Oncology received 245 more outperform votes than Alector when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 61.09% of users gave Alector an outperform vote.
10.0% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 0.6% of Cardiff Oncology shares are owned by insiders. Comparatively, 9.1% of Alector shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cardiff Oncology has higher earnings, but lower revenue than Alector. Cardiff Oncology is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Alector has a net margin of -257.54% compared to Cardiff Oncology's net margin of -3,688.31%. Alector's return on equity of -108.77% beat Cardiff Oncology's return on equity.
Summary
Alector beats Cardiff Oncology on 13 of the 18 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:TROV) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy TROV Stock Free TROV Stock Alerts